LB-100 - Phosphatase 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELB-100Cat. No.: HY-18597CAS No.: 1632032-53-1分式: CHNO分量: 268.31作靶點: Phosphatase作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 H2O : 48 mg/mL (178.90 mM)* means solub

2、le, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.7270 mL 18.6352 mL 37.2703 mL5 mM 0.7454 mL 3.7270 mL 7.4541 mL10 mM 0.3727 mL 1.8635 mL 3.7270 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 LB-100種蛋磷酸酶 2A (protein phosphatase 2A) 抑制劑，在 BxPc-3 和

3、Panc-1 細胞中，IC50 值分別為0.85 M 和 3.87 M。IC50 & Target IC50: 0.85 M (PP2 in BxPc-3 cell), 3.87 M (PP2 in Panc-1 cell)體外研究LB-100 inhibits the cell growth with IC50 of 2.3 M (in BxPc-3) or 1.7 M (in Panc-1 cell). In BxPc-3, Panc-1,1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEand SW1990 cells, LB-100 re

4、duces the PP2A activity by 30-50%. LB-100 increases concentration ofdoxorubicin within cells (2.5 fold to control) and sensitizes tumor cells to the cytotoxicity of doxorubicin. LB-100 increaseds VEGF secretion, and thus enhances HIF-1-VEGF mediated angiogenesis 1. LB-100 altersVE-cadherin integrity

5、 between endothelial cells. Pretreatment of LB-100 results in a nearly 40% increase indye passing through the HUVECs monolayer. LB-100 induces higher paracellular permeability of vascularendothelial cells potentially accounting for LB-100 increasing the concentration of doxorubicin in tumor cells2.

6、LB-100 downregulates Bcl-2 expression and enhances sorafenib-induced apoptosis in HCC cells 3.體內(nèi)研究 LB-100 (2 mg/kg, i.p.) decreases in a time-dependent manner the activity of PP2A in xenografts and livers innude mice. LB-100 does not alter the expression of the three PP2A subunits (PP2A_A, PP2A_B, a

7、ndPP2A_C) in cell lines, xenografts, or livers, as confirmed by immunoblotting. The combination of doxorubicin(1.5 kg/mL, every other day) and LB-100 (2 mg/kg, every other day) significantly slows the growth of tumorswith reduction of tumor volume in two animals with no effects on tumor growth in an

8、imals treated with singleagents 2.PROTOCOLKinase Assay 1 Cultured pancreatic cancer cells are treated with IC50 of LB-100 for each cell line or equal volume of vehiclefor 2 hours, and PP2A activity assays are then performed using Ser/Thr phosphatase assay kit. Cells arelysed with an ultrasonic cell

9、disruptor, and the PP2A concentration is measured using a Ser/Thr phosphataseassay kit according to the instructions. Assays for each cell line are performed in triplicate.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 Cytotoxicity is cond

10、ucted by using a Cell Counting Kit-8. Cells are seeded in 96-well plates with a density of3000 cells per well and are assessed after treatments following the CCK-8 protocol. Relative cytotoxicity isexpressed as a percentage of specic controls.MCE has not independently confirmed the accuracy of these

11、 methods. They are for reference only.Animal BALB/c nude mice are injected subcutaneously in the right flank with 1106 Huh-7 cells suspended in 200 LAdministration 2 PBS per mouse. After a tumor volume of 100 to 200 mm3 is reached, tumor-bearing mice are randomLyallocated to four groups: control gro

12、up, doxorubicin/cisplatin group, LB-100 group, and doxorubicin/cisplatinplus LB-100 group. For the doxorubicin plus LB-100 study (n=6 to 8), doxorubicin and LB-100 are injected i.p.at 1.5 and 2 mg/kg, respectively, on alternate days for a total of 16 days. For the cisplatin plus LB-100 study(n=8 to

13、10), cisplatin and LB-100 are injected at 3 and 2.5 mg/kg, i.p., respectively; cisplatin is injected every4 days and LB-100 is used every other day for 16 days. Control mice are injected with DMSO (in thedoxorubicin plus LB-100 group) or PBS (in the cisplatin plus LB-100 group) on the same schedule

14、as thedrug-treated animals. Tumor size is monitored every 3 or 4 days, and is calculated by the formula: tumorvolume=length width height/2. All mice are sacrificed at day 16, and xenografts are obtained, weighed,and fixed with 10% formaldehyde.MCE has not independently confirmed the accuracy of thes

15、e methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE Nat Commun. 2017 May 31;8:15580. Mol Cancer Ther. 2019 Mar;18(3):556-566. Biol Reprod. 2018 May 1;98(5):644-653.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Bai X, et al. Inhi

16、bition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1-VEGF mediated angiogenesis. Cancer Lett. 2014 Oct 7. pii: S0304-3835(14)00589-8.2. Bai XL, et al. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellularcarcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72.3. Fu QH, et al. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad